Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation

Monday, June 3, 2024

6:30 PM – 7:30 PM CT

Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific

PROGRAM FEATURES

• Online personalized quality-improvement poster-generation portal
• Downloadable whiteboard animations
• Shared decision-making video case

FACULTY

Meredith McKean, MD, MPH Director, Melanoma and Skin Cancer Research Sarah Cannon Research Institute Nashville, TN

PROGRAM OVERVIEW

This virtual, interactive, live activity is designed to help you optimize the development of treatment plans with your patients with advanced melanoma, incorporating the latest data on current and emerging immunotherapy approaches, effective strategies to mitigate and manage immunotherapy-associated adverse events, and expert appraisal of the therapeutic potential of ongoing lines of clinical investigation. The incorporation of multiple clinical case scenarios, illustrative animations, and didactic presentation will help to bring key messages home, emphasizing the importance of shared decision making and keeping the patient at the center of clinical care plans.

TARGET AUDIENCE

This virtually live activity is designed to meet the educational needs of oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician assistants who provide care for patients with advanced melanoma.

LEARNING OBJECTIVES

• Select first-line treatment for patients with unresectable or metastatic melanoma based on multidisciplinary consideration of evidence-based guidelines, the most updated immunotherapy clinical trial data, and shared decision making with the patient
• Apply best practices for overall management of adverse events experienced by patients receiving single-agent or combination immunotherapy for unresectable or metastatic melanoma
• Discuss ongoing clinical trials of combination immunotherapy strategies for melanoma, as well as their available data

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live event at [email protected]